Evaluating a Venom-Bioinspired Peptide, NOR-1202, as an Antiepileptic Treatment in Male Mice Models
Toxins · 2024
DOI: 10.3390/toxins16080342 ↗Kurz gefasst
Fachartikel in der Zeitschrift Toxins, 2024. Verfasst von Maria Varela Torres Quintanilha und 5 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Neuropharmacology, Department of Physiological Sciences, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, …. Hauptthemen laut MEDLINE: Anticonvulsants, Disease Models, Animal, Seizures. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Research Support of the Federal District, Foundation for Research Support of the Federal District:, National Council for Scientific and Technological Development:.
Abstract (Originalsprache)
Epilepsy, a neurological disorder characterized by excessive neuronal activity and synchronized electrical discharges, ranks among the most prevalent global neurological conditions. Despite common use, antiepileptic drugs often result in adverse effects and lack effectiveness in controlling seizures in temporal lobe epilepsy (TLE) patients. Recent research explored the potential of occidentalin-1202, a peptide inspired by Polybia occidentalis venom, in safeguarding Wistar rats from chemically induced seizures. The present study evaluated the new analog from occidentalin-1202 named NOR-1202 using acute and chronic pilocarpine-induced models and an acute kainic acid (KA) male mice model. NOR-1202 was administered through the intracerebroventricular (i.c.v.), subcutaneous, or intraperitoneal routes, with stereotaxic procedures for the i.c.v. injection. In the acute pilocarpine-induced model, NOR-1202 (i.c.v.) protected against generalized seizures and mortality but lacked systemic antiepileptic activity. In the KA model, it did not prevent generalized seizures but improved survival. In the chronic TLE model, NOR-1202′s ED50 did not differ significantly from the epileptic or healthy groups regarding time spent in spontaneous recurrent seizures during the five-day treatment. However, the NOR-1202 group exhibited more seizures than the healthy group on the second day of treatment. In summary, NOR-1202 exhibits antiepileptic effects against chemoconvulsant-induced seizures, but no effect was observed when administered systemically.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Neuropharmacology, Department of Physiological Sciences, Institute of Biological Sciences, University of Brasília, Brasília 70910-900, Brazil.
ORCID-Profile: Luana Cristina Camargo, Marcia Renata Mortari
Förderung
- Foundation for Research Support of the Federal District
- Foundation for Research Support of the Federal District:
- National Council for Scientific and Technological Development:
- Coordenação de Aperfeicoamento de Pessoal de Nível Superior:
- Conselho Nacional de Desenvolvimento Científico e Tecnológico—CNPq
- Fundação de Apoio à Pesquisa do Distrito Federal—FAPDF
- Coordenação de Aperfeiçoamento de Pessoal de Nível Superior—CAPES
Zitieren
APA
Quintanilha, M. V. T., Gobbo, G. A. M., Pinheiro, G. B., Souza, A. C. B., Camargo, L. C., & Mortari, M. R. (2024). Evaluating a Venom-Bioinspired Peptide, NOR-1202, as an Antiepileptic Treatment in Male Mice Models. Toxins. https://doi.org/10.3390/toxins16080342
Vancouver
Quintanilha MVT, Gobbo GAM, Pinheiro GB, Souza ACB, Camargo LC, Mortari MR. Evaluating a Venom-Bioinspired Peptide, NOR-1202, as an Antiepileptic Treatment in Male Mice Models. Toxins. 2024. doi:10.3390/toxins16080342
BibTeX
@article{Quintanilha2024,
author = {Quintanilha, Maria Varela Torres and Gobbo, Giovanna de Azevedo Mello and Pinheiro, Gabriela Beserra and Souza, Adolfo Carlos Barros de and Camargo, Luana Cristina and Mortari, Marcia Renata},
title = {Evaluating a Venom-Bioinspired Peptide, NOR-1202, as an Antiepileptic Treatment in Male Mice Models},
journal = {Toxins},
year = {2024},
doi = {10.3390/toxins16080342}
}
EUVIMED